Skip to Main Content

HLAB-002 of ANS-6637 for Alcohol Use Disorder

Conditions

Alcohol Addiction | Mental Health & Behavioral Research

Phase II

What is the purpose of this trial?

Brief Summary:

The primary objective of this study is to evaluate the effects of two different doses of ANS-6637, 200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day, and matched placebo, on alcohol cue-elicited alcohol craving during a human laboratory paradigm after 1 week of daily dosing among subjects with moderate to severe alcohol use disorder (AUD) as confirmed by the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5™).

  • Trial with
    National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • Start Date
    10/01/2019
  • End Date
    07/31/2020
Trial Image

For more information about this study, contact:

Thomas Liss

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/15/2019
  • Study HIC
    #2000025902